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3CHAPTER 1
Introduction
4The metabolic syndrome (METS) is a cluster of lipid and non-lipid factors that increase
cardiovascular risk [1]. The National Cholesterol Educational Program and its Third Adult
Treatment Panel (NCEP ATP-III) have established diagnostic criteria for the METS, which
are met when three or more of the following are present: abdominal obesity, decreased high-
density lipoprotein cholesterol (HDL-C) levels and increased serum triglycerides (TG), fasting
glucose and/or blood pressure levels [2].
A. Prevalence
Prevalence of the METS is higher in women, especially those of Latin America ancestry [3],
with an increased frequency observed in relation to age and the menopausal status. Indeed,
during the menopausal transition there is an emergence of features related to the METS:
obesity, dyslipidemia, diabetes, hyperinsulinism, hypertension and co-morbid conditions [4],
possibly but not totally related to increasing estrogenic deficiency [5]. Rates may also vary
according to the studied population from 22% [6] to 34% as determined in seven cross-
sectional studies of non-diabetic Europeans [7]. This syndrome increases cardiovascular
morbidity and mortality and the risk of developing diabetes [8].
B. The effect of the menopause over female weight
The prevalence of abdominal obesity is nearly double that of general obesity, with rates in
North American women calculated for 2008 in 65.5% (aged 40-59 years) and 73.8% (60
years or more)[9]. It has been suggested that body mass index (BMI) but not menopausal
status determines central adiposity in postmenopausal women. However, there is substantial
evidence that the perimenopause is associated with a more rapid increase in fat mass and
redistribution of fat to the abdomen, resulting in a transition from a gynoid to an android
pattern of fat distribution and an increase in total body fat [10]. Moreover, postmenopausal
women have greater amounts of intra-abdominal fat as compared to premenopausal ones,
as determined with several radiological modalities [11]. Waist circumference represents both
5subcutaneous and visceral adipose tissue depot size and correlates closely with the risk for
cardiovascular disease. In women, it is also closely associated with dyslipidemia [12].
Abdominal fat is considered an endocrine organ as it has the capacity to secrete
adipokines and other active substances closely related to metabolic diseases: insulin
resistance, type 2 diabetes and the METS [13]. Both, the menopausal transition and aging,
are associated with changes in adipose tissue metabolism, which contribute to the
accumulation of body fat after menopause [14]. Deleterious changes in inflammatory markers
and adipokines correlate strongly with increased visceral adiposity after the menopause [15].
Waist circumference significantly changes in relation to the time since final menstrual
period. Moreover, significant increases in central abdominal fat have been reported from
longitudinal studies in Caucasian and Asian women [16]. It has been observed that when
non-obese premenopausal women are followed-up for several years, significant increases in
total, percentage and truncal and visceral fat mass occur [16]. Women who later became peri
or postmenopausal displayed a significant increase in visceral fat compared with baseline
[16].
C. The impact of increased weight over menopausal symptoms
Severity and prevalence of menopausal symptoms relate several factors. These include
not only the hormonal changes imposed by the transition, but also psychosocial factors. As
weight increased during the menopausal transition, so do menopausal symptoms. Obesity is
an independent risk factor for more severe menopausal symptoms [17,18].
Reduction of weight, BMI and abdominal circumference have been associated with a
significant reduction in vasomotor symptoms women who are overweight and obese [19].
The combination of dietary modification and exercise also has positive effects on health
related quality of life (HRQOL) and psychological health, which may be greater than that from
exercise or diet alone [20]. Improvements in weight, aerobic fitness and psychosocial factors
may mediate some of the effects of these interventions on HRQOL [20]. Weight loss in
6overweight and obese women improves psychological wellbeing, HRQOL, self-esteem and
health practices [21]. In addition, dietary weight loss and exercise exert a positive effect over
insulin resistance in postmenopausal women, which together with a decrease in menopausal
symptoms may potentially decrease cardiovascular risk.
D. The METS a state of pro-inflammation and endothelial dysfunction
The METS is associated with increased inflammation, endothelial dysfunction, oxidative
stress and abnormalities in both the macro- and microvasculature [22]. Adipocytes and
adipose-tissue macrophages are involved in the production of IL-6, which is one of the main
mediators of chronic inflammation [23]. Elevated IL-6 is an established risk factor for
cardiovascular events in women after the menopause; thus, it is interesting to find that the
presence of METS, rather than the menopause itself, relates to increased IL-6 levels. IL-6
serum levels are associated with visceral adipose tissue and can influence insulin levels [24].
On the other hand, it has been reported that IL-6 polymorphisms may play a role in the
pathogenesis of the METS through the modulation of IL-6 levels [25].
F. Endothelial dysfunction during pregnancy as a model for future METS risk
Preeclampsia is a leading cause of maternal mortality and morbidity worldwide [26].
Epidemiological data indicate that women complicated with preeclampsia are more likely to
develop future cardiovascular disease (CVD). Population-based studies
relate preeclampsia to an increased risk of later chronic hypertension (RR, 2.00 to 8.00) and
cardiovascular morbidity/mortality (RR, 1.3 to 3.07), compared with normotensive pregnancy
[27]. Women who develop preeclampsia before 36 weeks of gestation or have multiple
hypertensive pregnancies are at highest risk (RR, 3.4 to 8.12). The underlying mechanism
for the remote effects of preeclampsia is complex and probably multifactorial. Many risk
factors are shared by CVD and preeclampsia, including endothelial dysfunction, obesity,
hypertension, hyperglycemia, insulin resistance, and dyslipidemia. Therefore, it has been
proposed that the METS may be a possible underlying mechanism common to CVD
7and preeclampsia. Follow-up and counseling of women with a history of preeclampsia may
offer a window of opportunity for prevention of future disease [27].
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9CHAPTER 2
Aim and outline of the thesis
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The aim of this thesis was to explore several clinical, biochemical/molecular and
etiological aspects of the METS occurring after the menopause. In chapter 3 the prevalence
of the METS and factors relating to each of its composing factors are explored in a sample of
postmenopausal Ecuadorian women. The results suggest that the prevalence of the METS
was high and associated to metabolic and lipid abnormalities. Abdominal obesity was related
to lower education; hence, there is a need to educate high risk populations and increase
awareness of the problem.
Clinical aspects of postmenopausal METS are analyzed in chapter 4. The first study
analyzed the hypothesis that the METS or its components can cause a negative impact on
menopausal symptoms in postmenopausal women as determined with a validated tool (The
MENQOL). Results confirmed this hypothesis, as menopausal symptoms were significantly
related to components of the syndrome. Indeed, abdominal obesity related to hot flushes,
depression and muscle and joint pain.  Given these results, in a second study it was aimed at
determining if the METS or its components would significantly affect sleep (insomnia) in
postmenopausal women by means of The Athens Insomnia Scale. Study results indicated
that this association was not found yet was related to other psycho-somatic female and
partner issues.
Biochemical aspects related to inflammation and endothelial dysfunction encountered
among postmenopausal women with the METS are explored in chapter 5. Nitric oxide (NO)
and pro-inflammatory cytokine levels (IL-6 and TNF-α) were measured in postmenopausal
women with and without the METS. Results indicated that those with the METS displayed
higher IL-6 and NO levels as compared to those without the syndrome, with significant
correlations found between studied analytes and some of the METS components. Finding
higher instead of lower NO levels in those with the METS is discussed. Several markers
related to angiogenesis, inflammation and endothelial function were measured in the second
study using multiplex technology. Higher IL-6 (marker of inflammation) and lower uPA
11
(marker of endothelial dysfunction) levels were found among those with postmenopausal
METS. These were mainly related to metabolic and lipid abnormalities.
Several studies have determined that endothelial dysfunction occurring as a
consequence of pregnancy related complications (i.e preeclampsia) may indeed increase the
risk of presenting the METS and its composing features and further increase cardiovascular
risk. Evaluation of endothelial function from a biomolecular perspective has been performed
in women with preeclampsia however only in the maternal side. Studies assessing the
umbilical fetal circulation are scarce or lacking. Given our prior results regarding NO and the
METS, and as a first step, chapter 6 aimed at analyzing endothelial dysfunction by
measuring NO, ADMA and VEGF levels in fetal circulation of pregnant women with severe
preeclampsia and discuss the possible role of gestational endothelial dysfunction in the
genesis of postmenopausal METS and further cardiovascular risk. In addition, DNA was
extracted from umbilical vein to determine the frequency of VEGF gene single nucleotide
polymorphisms. Results found that women with severe preeclampsia displayed higher NO
and ADMA fetal circulating levels (vein and artery) and lower VEGF umbilical vein levels.
There was a significant trend of finding lower VEGF levels in the presence of -2578 CC and -
1154 AG genotypes. As a next step, further research is warranted to confirm these findings
and to find a biomolecular marker capable of establishing the link between endothelial
dysfunction found in preeclampsia and postmenopausal METS.
Finally, the biological mechanisms involved in cardiovascular disease during mid-life
are analyzed in chapter 7, by means of a critical review. Particular emphasis is given to
biochemical markers and indicators of cardiovascular dysfunction and damage.
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Summary
1. The prevalence of the METS and factors relating to each of its composing factors were
high and associated to metabolic and lipid abnormalities. Abdominal obesity was
related to lower education; hence there is a need to educate high risk populations and
increase awareness of the problem.
2. Components of the syndrome were significantly related to an increase in the severity of
menopausal symptoms. Indeed, abdominal obesity related to hot flushes, depression
and muscle and joint pain.
3. As determined by the The Athens Insomnia Scale, the METS or its components did not
significantly affect sleep (insomnia). Other psycho-somatic female and partner issues
correlated to insomnia in postmenopausal women.
4. Postmenopausal women with the METS displayed higher IL-6 and NO levels as
compared to those without the syndrome, with significant correlations found between
studied analytes and some of the METS components. The study found an interesting
scenario: pro-inflammation in the presence of high NO levels. We hypothesized that
analyzed women with the METS or any of its components were still at an earlier stage
of the disease in which NO production may be increased in order to protect against the
adverse effects of chronic inflammation when instead lower NO levels would ensue as
a consequence of endothelial dysfunction. Interesting was finding that age and time
since the menopause positively correlated with both cytokine levels indicating that in
time chronic inflammation will ensue. Our results support the “window of opportunity”
theorem in which lower estrogen levels have still not produced irreversible endothelial
damage. Hence, female lifestyle changes and preventive measures at this stage are
crucial and should be highly encouraged.
5. Postmenopausal women with the METS displayed higher IL-6 (marker of inflammation)
and lower uPA (marker of endothelial dysfunction) levels. These were mainly related to
metabolic and lipid abnormalities.
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6. Women with severe preeclampsia displayed higher NO and ADMA fetal circulating
levels (vein and artery) and lower VEGF umbilical vein levels. There was a significant
trend of finding lower VEGF levels in the presence of -2578 CC and -1154 AG
genotypes. Results of this study provides insights for new study designs using
preeclampsia as a study model of endothelial dysfunction that will aim at finding a
biomolecular marker capable of establishing the link between endothelial changes
found in preeclampsia as well as in postmenopausal METS.
7. The analysis of inflammatory and oxidative stress biomarkers and genetic factors
appear promising in providing new basic information and development in the clinical
practice.  Nevertheless, we yet need to understand the entity of sex-related differences
in cardiovascular disease and whether multiple biomarkers contribute to improved
coronary heart disease risk prediction when compared to assessment using traditional
risk factors in postmenopausal women. This knowledge will allow to identify more
important sex-associated biomarkers or panels to optimize diagnostic and therapeutic
strategies targeted for men and women when appropriate.
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